Wide Ranks

CPIX

Cumberland Pharmaceuticals Inc.

1.37

Top Statistics
Market Cap 19 M Forward PE 9.79 Revenue Growth -9.90 %
Current Ratio 1.13 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -29.55 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -8.22 Enterprise / Revenue 0.6230 Price To Sales Trailing12 Months 0.5230
Profitability
Profit Margins -29.55 % Operating Margins -18.65 %
Balance Sheet
Total Cash 17 M Total Cash Per Share 1.25 Total Debt 21 M
Total Debt To Equity 87.78 Current Ratio 1.13 Book Value Per Share 1.77
All Measures
Short Ratio 120.00 % Message Board Id finmb_25240322 Shares Short Prior Month 40535
Return On Equity -0.3607 City Nashville Uuid fbb0fe28-9752-3ce1-bfca-efe25634b947
Previous Close 1.11 First Trade Date Epoch Utc 1 B Book Value 1.77
Beta 0.2190 Total Debt 21 M Volume 2 M
Price To Book 0.7744 Fifty Two Week Low 1.04 Total Cash Per Share 1.25
Total Revenue 36 M Shares Short Previous Month Date 1 B Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -18.65 % Net Income To Common -10870362
Short Percent Of Float 0.0114 Implied Shares Outstanding 14 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 247440 Average Volume10days 247440
Total Cash 17 M Next Fiscal Year End 1 B Revenue Per Share 2.61
Held Percent Insiders 0.4472 Ebitda Margins -7.58 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.11
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.21
Open 1.12 Free Cashflow 3 M State TN
Dividend Yield 0.00 % Return On Assets -0.0564 Time Zone Short Name EST
Trailing Eps -0.7600 Day Low 1.07 Address1 1600 West End Avenue
Shares Outstanding 14 M Price Hint 4 Target High Price 0.0000
Website https://www.cumberlandpharma.com 52 Week Change -0.1646 Average Volume 71810
Forward Eps 0.1400 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 92.60 % Is_sp_500 False Regular Market Day High 1.59
Profit Margins -29.55 % Debt To Equity 87.78 Fifty Two Week High 2.36
Day High 1.59 Shares Short 89608 Regular Market Open 1.12
Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 % Enterprise To Revenue 0.6230
Revenue Growth -9.90 % Shares Percent Shares Out 0.0064 Operating Cashflow -1476683
Currency USD Time Zone Full Name America/New_York Market Cap 19 M
Is_nasdaq_100 False Zip 37203 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Cumberland Pharmaceuticals Inc. Regular Market Day Low 1.07
Held Percent Institutions 0.1469 Current Price 1.37 Address2 Suite 1300
Enterprise To Ebitda -8.22 Financial Currency USD Current Ratio 1.13
Gross Margins 83.31 % Industry Disp Drug Manufacturers - Specialty & Generic Country United States
Float Shares 7 M Two Hundred Day Average 1.50 Enterprise Value 22 M
Price To Sales Trailing12 Months 0.5230 Forward PE 9.79 Regular Market Volume 2 M
Ebitda -2786334 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.

The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.

In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension.

Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases.

The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.